Assenagon Asset Management S.A. Protara Therapeutics, Inc. Transaction History

Assenagon Asset Management S.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 06, 2023	SELL	$1.64 - $2.93 $21,680 - $38,734	-13,220 Reduced 45.51%	15,831 $26,000
Q2 2023 Jul 25, 2023	BUY	$2.27 - $3.59 $26,593 - $42,056	11,715 Added 67.58%	29,051 $69,000
Q4 2022 Jan 12, 2023	SELL	$2.43 - $3.7 $99,758 - $151,896	-41,053 Reduced 70.31%	17,336 $46,000
Q2 2022 Jul 27, 2022	BUY	$2.8 - $5.33 $41,014 - $78,073	14,648 Added 33.49%	58,389 $171,000
Q1 2022 Apr 25, 2022	BUY	$4.19 - $6.9 $183,274 - $301,812	43,741 New	43,741 $224,000

10.7M

1.8K

Ticker TARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,267,400
Market Cap $60.7M
Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.